Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lumos Pharma Inc
(NQ:
LUMO
)
3.900
-0.010 (-0.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lumos Pharma Inc
< Previous
1
2
Next >
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
May 08, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
May 03, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
April 27, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
April 19, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
March 09, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
March 05, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
March 01, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
February 28, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
February 15, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
January 03, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
December 12, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
November 29, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
November 14, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
November 14, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
July 27, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.